Fragment-Based Drug Discovery against Mycobacteria: The Success and Challenges

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Mycobacterial Infections

Background:

• Drug-resistant Mycobacterium tuberculosis (Mtb) and non-tuberculous mycobacteria (NTM) represent a significant global health challenge.
• There is an urgent need for novel anti-mycobacterial agents to combat these resistant strains.

Purpose of the Study:

• To review fragment-based drug discovery (FBDD) as a key strategy for identifying new anti-mycobacterial compounds.
• To highlight the application of FBDD in targeting essential mycobacterial proteins (PurC, ArgB, MmpL3, TrmD).
• To discuss the challenges and potential solutions in FBDD for Mtb and NTM drug development.

Main Methods:

• Focus on virtual, computational, and biophysical techniques for fragment identification.
• Utilizes specialized methods like X-ray crystallography and nuclear magnetic resonance spectroscopy.
• Employs FBDD to overcome drawbacks of traditional drug discovery, such as toxicity and bioavailability assessment.

Main Results:

• FBDD successfully identifies potent fragment molecules against Mtb and NTM targets.
• This approach offers advantages over structure-based drug design and high-throughput screening.
• FBDD aids in overcoming limitations of traditional drug discovery methods.

Conclusions:

• FBDD is a valuable and ingenious approach for developing novel anti-mycobacterial drugs.
• Addressing FBDD challenges is crucial for advancing new treatments for Mtb and NTM infections.
• Insights from FBDD can lead to effective therapies for drug-sensitive and drug-resistant mycobacterial diseases.